Teva CEO Levin faces pressure from long-suffering investors

Teva ($TEVA) investors are waiting for a word from CEO Jeremy Levin. But not just any word. As Reuters reports today, the company's long-suffering shareholders want a little love from their new chief."The most important signal (shareholders) need to hear on the record from Levin is 'whatever it takes I will protect you'," RCM Capital Management's Dan Hunt told the news service. Article


Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.